Skip to main content

Table 3 Multivariate odds ratios (95% confidence intervals) for physicians' beliefs about enfuvirtide regimens compared with standard oral-based regimens for treatment-experienced patientsa

From: Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives?

Physician belief themes

Enfuvirtide-prescriber category

Case scenarios

 

'Higher' (≥ 5 patients currently prescribed)b

(n = 175)

'Non' (no patients currently prescribed)c

(n = 120)

Physicians selecting enfuvirtide option

   

Case 1d

(n = 323)

Case 2e

(n = 214)

Personal confidence in the efficacy of enfuvirtide and its use in practice

3.35¶

(2.20, 5.08)

0.32¶

(0.19, 0.53)

2.44¶

(1.62, 3.66)

2.10‡

(1.44, 3.07)

Enfuvirtide is associated with treatment refusal and nonadherence

NS

2.05‡

(1.29, 3.25)

0.59†

(0.40, 0.86)

0.69*

(0.47, 0.99)

Enfuvirtide is difficult to justify in terms of time and resources

0.63*

(0.42, 0.94)

1.69*

(1.07, 2.64)

0.57‡

(0.39, 0.83)

NS

An enfuvirtide treatment offer is likely to jeopardize patients' trust

0.56‡

(0.37, 0.83)

1.86†

(1.19, 2.92)

NS

NS

Patients are likely to perceive that drawbacks of enfuvirtide outweigh its benefits

NS

NS

NS

NS

Concerns about the risks of self-injectable therapies

NS

NS

0.52¶

(0.37, 0.78)

NS

Enfuvirtide is more suitable for nonadherent/chaotic patients

NS

NS

NS

2.44¶

(1.67, 3.57)

  1. aControlling for number of patients with HIV managed by each physician and for country.
  2. For the statistical comparisons:
  3. bCompared with lower and nonprescribers.
  4. cCompared with higher and lower prescribers.
  5. dCompared with physicians who did not select the enfuvirtide option.
  6. eCompared with physicians of patients who were currently prescribed enfuvirtide.
  7. *p < 0.05; †p < 0.01; ‡p < 0.005, ¶p < 0.001.
  8. NS = no statistically significant difference between comparators.